FTC Requires Divestment in Aurobindo Pharma's $250 Million Lannett Acquisition

The Quick Take

• The US FTC approved Aurobindo Pharma's $250 million Lannett acquisition subject to a divestment requirement to address antitrust concerns
• Aurobindo must divest specific generic drug products where the combined entity would hold excessive market share in individual therapeutic categories
• The deal represents Aurobindo's strategy to expand US generic pharmaceutical market share, a key growth lever for the Indian pharma giant

The US Federal Trade Commission approved Aurobindo Pharma's $250 million acquisition of Lannett Company with a divestment condition, requiring the Indian generic pharmaceutical manufacturer to sell specific drug products where the combined entity's market position would create antitrust concerns. FTC divestment requirements in pharmaceutical mergers typically target generic drug categories where the acquiring and target companies both manufacture or market products, creating concentration that could reduce competitive pricing pressure for patients and healthcare systems.

Aurobindo Pharma's acquisition of Lannett represents a strategic expansion of its US market presence, which has been a key revenue driver for the Hyderabad-based company. Lannett is a Philadelphia-based generic drug manufacturer with a portfolio of established generic medications. The $250 million deal price reflects a significant premium for Lannett's US distribution capabilities, regulatory approvals, and customer relationships—assets that are difficult for Indian generic manufacturers to replicate organically.

The FTC divestiture condition is a standard mechanism for preserving competition in pharmaceutical markets during consolidation. Aurobindo will likely sell the flagged products to a third-party generic manufacturer as a condition of deal closing, preserving market access and competitive pricing in affected drug categories. For investors in Indian pharma companies with US exposure, this transaction sets a regulatory precedent: large-scale US acquisitions by Indian generic manufacturers will face antitrust scrutiny proportional to therapeutic area overlap, adding complexity and cost to future deal timelines.

Synthesized from 1 source.